^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IRAK-4 degrader

    Related drugs:
    30d
    ZEN: A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, Sanofi | N=156 --> 70 | Trial primary completion date: Jun 2026 --> Oct 2025
    Enrollment change • Trial primary completion date
    30d
    ADVANTA: Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, Sanofi | N=200 --> 70 | Trial primary completion date: Jul 2026 --> Oct 2025
    Enrollment change • Trial primary completion date
    2ms
    Key cell cycle genes in cervical cancer and their potential role in neuromuscular complications: a bioinformatics perspective. (PubMed, Eur J Transl Myol)
    Gene expression profiles related to cervical cancer (GSE63514, GSE6791, GSE52903, and GSE9750) were retrieved from the GEO database...The specific genes associated with the cell cycle can act as prognostic biomarkers and may also have an influence in mediating neuromuscular complications due to their impact on mitotic control and molecular signaling pathways throughout the body. This latter aspect is helpful for the prognosis of cancer, including cervical cancer, as well as for the multidisciplinary treatment of neuromuscular symptoms that some cervical cancer patients may have.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • CCNA2 (Cyclin A2) • CDC20 (Cell Division Cycle 20) • CDK1 (Cyclin-dependent kinase 1)
    3ms
    A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov)
    P2, N=90, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    3ms
    A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old (clinicaltrials.gov)
    P1, N=78, Recruiting, Biogen | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    Downregulation of ANKRD22 and its prognostic significance in squamous cell carcinoma of the cervix: a bioinformatics analysis based on public datasets. (PubMed, Transl Cancer Res)
    Gene expression profiles were obtained from GEO datasets (GSE63514, GSE6791), and RNA sequencing and clinical data were obtained from The Cancer Genome Atlas...ANKRD22 downregulation is associated with poor prognosis in SCC of the cervix. While these findings suggest prognostic relevance, further experimental studies are necessary to validate ANKRD22's clinical utility.
    Journal
    |
    ANKRD22 (Ankyrin Repeat Domain 22)
    4ms
    A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, BeiGene
    New P2 trial
    5ms
    ADVANTA: Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov)
    P2, N=200, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    5ms
    ZEN: A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov)
    P2, N=156, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    8ms
    A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa (clinicaltrials.gov)
    P1/2, N=12, Not yet recruiting, Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
    New P1/2 trial
    8ms
    A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
    New P1/2 trial
    10ms
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases (clinicaltrials.gov)
    P1, N=195, Recruiting, BeiGene | N=92 --> 195
    Enrollment change